<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01273974</url>
  </required_header>
  <id_info>
    <org_study_id>89-5905</org_study_id>
    <nct_id>NCT01273974</nct_id>
  </id_info>
  <brief_title>The Immunogenicity of Intradermal Influenza Vaccination in Hemodialysis Patients</brief_title>
  <official_title>The Comparison of Serum Antibody Response to Standard Intramuscular and Half Dose Intradermal Influenza Vaccine in Hemodialysis Patients in Shiraz City in 1388.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether half-dose intradermal influenza vaccine is
      as immunogenic as standard dose intramuscular vaccine in hemodialysis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemodialysis patients are at high risk of influenza infection due to suppress immune
      status.It is recommended to immunize them against influenza annually.in intradermal
      vaccination antigens directly present to the large numbers of antigen-presenting cells in the
      skin and it may cause greater immunogenicity than in the intramuscular method. Reduced-dose
      intradermal influenza vaccine is immunogenic in healthy adult, patients with solid cancer and
      three groups of immunocompromized patients including Rheumatologic patients treated with
      anti-TNF, HIV-infected and stem cell transplanted patients.

      In this study we compare the efficacy of influenza vaccines in half dose intradermal and
      standard intramuscular methods among hemodialysis patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>vaccine effectiveness</measure>
    <time_frame>3 months</time_frame>
    <description>serum antibody response measured by ELIZA method time frame:1 and 3 months after vaccination</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Hemodialysis Patients</condition>
  <arm_group>
    <arm_group_label>intradermal influenza vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>intramuscular influenza vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>intradermal influenza vaccine</intervention_name>
    <description>0.25ml ,intradermal</description>
    <arm_group_label>intradermal influenza vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>intramuscular influenza vaccine</intervention_name>
    <description>0.5ml,intramuscular</description>
    <arm_group_label>intramuscular influenza vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients under chronic hemodialysis

        Exclusion Criteria:

          -  history of flu infection in last month

          -  history of flu vaccination in 2009

          -  hospitalization in last month

          -  taking immune suppressants drugs

          -  hemodialysis less than twice weekly
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad mahdi Sagheb</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiraz University Of Medical Science</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samira Saeian</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiraz University Of Medical Science</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jamshid Roozbeh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiraz University Of Medical Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shiraz University Of Medical Science</name>
      <address>
        <city>Shiraz</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://www.pubmed.com</url>
  </link>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2011</study_first_posted>
  <last_update_submitted>January 10, 2011</last_update_submitted>
  <last_update_submitted_qc>January 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2011</last_update_posted>
  <keyword>intradermal influenza vaccine</keyword>
  <keyword>hemodialysis patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

